Tarsus Pharmaceuticals, Inc. (TARS)
| Previous close | 34.63 |
| Open | 35.75 |
| Bid | 36.23 x 100 |
| Ask | 36.46 x 100 |
| Day's range | 35.51 - 36.82 |
| 52-week range | 12.57 - 40.40 |
| Volume | |
| Avg. volume | 697,548 |
| Market cap | 1.37B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.62 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 53.38 |
GlobeNewswireTarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
IRVINE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1.30 p.m. PT / 4.30 p.m. ET on Wednesday, May 8, 2024 to report its first quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the
- GlobeNewswire
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
IRVINE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it has secured $200 million in committed capital from funds associated with Pharmakon Advisors, LP. Tarsus has elected to draw $75 million on the closing date, April 19, 2024, with the remaining $125 million of committed capital avai
Simply Wall St.Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14%
Insiders who bought Tarsus Pharmaceuticals, Inc. ( NASDAQ:TARS ) stock lover the last 12 months are probably not as...
